Blood Cultures Articles & Analysis
38 news found
The Accelerate Arc System cuts hours of wait time and numerous manual steps to deliver Identification (ID) results Unlocks rapid microbial ID from positive blood cultures for the large installed base of MALDI system users Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of ...
The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. ...
Today’s gold standard for detecting sepsis in the laboratory setting is microbiological culture identification. However, the prediction of positive blood culture results remains a very difficult task since positive blood culture results in approx. only 20% of the cases6 due to low sensitivity. ...
Designed for labs with MALDI platforms, the Accelerate Arc Module and BC kit is a novel application of inline centrifugation and automated sample prep techniques, which together with the blood culture (BC) kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate. ...
” About Specific Specific Diagnostics has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid detection and identification of microorganisms as they grow in culture. Its first commercial application applies this fundamental new platform to the rapid determination of antimicrobial susceptibility directly ...
“The data presented at ECCMID represents an important step in providing a workflow solution to help automate sample preparation for rapid and accurate microbial identification from positive blood cultures,” said Shelley Campeau, PhD, D(ABMM), co-author of the studies and Director of Scientific and Clinical Affairs, Accelerate Diagnostics. ...
The patented RPIDD method is going to revolutionize the traditional first line clinical diagnostics for infectious diseases such as blood culture, PCR (etc), and we are convinced that a rapid molecular liquid biopsy based diagnostics approach for infectious diseases will disrupt the current approaches and hence in due course potentially reduce infected ...
In September 2021, the company received Breakthrough Device Designation from the FDA for positive blood culture and sterile body fluid sample indications for NGP. In October 2021, the company received a $2.8 million award from the U.S. ...
Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets. ...
Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture sets, announced the signing of a recent agreement with AllSpire Health GPO. ...
About Specific Specific Diagnostics has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid detection and identification of microorganisms as they grow in culture. Its first commercial application applies this fundamental new platform to the rapid determination of antimicrobial susceptibility directly from ...
This new agreement provides educational resources and programs to MHA members on best practices in blood culture collection and the role of clinically proven solutions, including Steripath, in virtually eliminating blood culture contamination at the source. ...
Specific Diagnostics today announced formation of its US commercial sales, service, support and marketing teams in anticipation of the launch of the Reveal Rapid AST System for blood infection samples. Following 11 studies across France and England comprising over 1,400 clinical positive blood culture samples, yielding overall accuracy of 97.8%, ...
“By embracing an innovative approach to blood culture processing, CMS can advance the accuracy of the diagnosis of blood stream infections including sepsis to improve patient outcomes and avoid costly complications from misdiagnosis,” said Representative Gus Bilirakis. ...
“Having participated in the development of the rapid ID market with GenMark’s syndromic PCR solution, I know from that our leading customers now need an affordable, high throughput, and easy to use rapid AST, especially for blood infections. Specific’s Reveal is the best-in-class instrument to meet this need, and I am keenly looking forward to building a ...
” About Specific Specific Diagnostics has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid detection and identification of microorganisms as they grow in culture. Its first commercial application applies this fundamental new capability to the rapid determination of antimicrobial susceptibility directly ...
The six studies reported reductions in blood culture contamination ranging from 80% to 100% with sustained rates of less than 1% in each. ...
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the expansion of its senior leadership team with the addition of Patrick O’Malley as Chief Financial Officer. ...
Magnolia Medical Technologies, Inc., inventors of Steripath, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the addition of Joseph Bishop to the executive leadership team as Senior Vice President of Operations and Product Development. ...
Last month, Selux received Breakthrough Device Designation from the FDA for positive blood culture and sterile body fluid sample indications for NGP. The Breakthrough Devices Program provides patients and providers with timely access to medical devices by speeding up their development, assessment, and review process while preserving statutory standards for ...